Klin Farmakol Farm. 2015;29(3):124-128

ABP501, SB5.

Hana Ciferská, Monika Urbanová

Revmatologický ústav a Revmatologická klinika 1. LF UK Praha

Biosimilars in treating inflammatory rheumatic diseases

The advent of biological therapy has significantly positively influenced the prognosis and quality of life of patients with rheumatoid

arthritis (RA) and ankylosing spondylitis (AS). The administration of biologic drugs results in suppressing disease activity, affecting x-ray

progression, and improving the mobility and quality of life of the patient. The benefit of this treatment largely exceeds the possible risks

associated with its administration. Biological therapy is associated with high costs that, to a certain degree, can be reduced by using

biosimilar drugs, or biosimilars. Biosimilars are similar to the original biological medications. Biologics are a product of live organisms

and exhibit natural variability. Biosimilars cannot be referred to as a generic drug for these very properties, it is impossible to precisely

define their structure. Among the first registered biosimilars indicated to treat inflammatory rheumatic diseases was an agent based on

infliximab, i. e. CT-P13 that exhibited a good efficacy and safety comparable with that of the original medication. Currently, the biosimilar

infliximab CT-P13 is registered for the indication of RA, AS, and psoriatic arthritis in the Czech Republic.

Keywords: biosimilars, rheumatoid arthritis, ankylosing spondylitis, infliximab, etanercept, CT-P13, BOW015, SB2, SB4, HD203, ABP501, SB5

Published: December 1, 2015  Show citation